DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants)

Therapeutic Areas

Other DiseasesNeoplasmsImmune System Diseases+ [10]

Active Indication

InflammationLocalized Prostate CarcinomaColorectal Cancer+ [36]

Inactive Indication

AdenocarcinomaAdvanced cancerAdvanced Pancreatic Adenocarcinoma+ [2]

Originator Organization

The University of Texas MD Anderson Cancer Center

Active Organization

Seoul National UniversityFranklin Square Hospital Center, Inc.

University of Pennsylvania

+ [43]

Inactive Organization

Seattle Children's Hospital

The Affiliated Hospital of Qingdao University3i Nature SAS

+ [1]

Drug Highest PhaseApproved

First Approval Date-

RegulationOrphan Drug (US)

Structure

Molecular FormulaC21H20O6

InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N

CAS Registry458-37-7

644

Clinical Trials associated with Curcumin

CTRI/2024/11/076875 / Not yet recruitingPhase 4

A Single Center, Randomized, Double blind, Placebo Controlled Pilot Study to Evaluate the Efficacy, Safety and Tolerability of Turmeric Lemonade Energy Drink (Bioactive Curcumin Plus Green Tea Plus Ginger Plus Lemon Plus Lime) manufactured by Golden Tiger Life Corp in the Treatment of Patients with Moderate Osteoarthritis of Knee. - Nil

Start Date06 Nov 2025

Sponsor / Collaborator

Tiger Companies

NCT06359665 / Enrolling by invitationPhase 1IIT

A Randomized Controlled Trial of Oral Curcumin for the Treatment of Pain of CMC Arthritis

The goal of this clinical trial is to learn about the use of turmeric (Curcumin) as a treatment for pain of thumb-joint arthritis. Turmeric is commonly being used as an over-the-counter treatment for musculoskeletal pain. Clinical trials have demonstrated a pain-relief benefit for knee osteoarthritis, however no clinical trial has been performed to establish efficacy of curcumin in humans for thumb-joint arthritis. The main question[s] it aims to answer are:
* Is Turmeric more effective than placebo at relieving pain for thumb-joint arthritis? A placebo is a look-alike substance that contains no active drug.
* Is Turmeric more effective than placebo at improving patient-reported outcomes for CMC arthritis?
* Is Turmeric safe for participants with thumb-joint arthritis?
Participants will:
* take 4 weeks of daily Turmeric capsules,
* take 4 weeks of daily placebo capsules
* answer daily surveys about how they are feeling and functioning.

Start Date01 Jan 2025

Sponsor / Collaborator

University of Virginia

CTRI/2024/12/077766 / Not yet recruitingPhase 2/3

A randomized double-blinded placebo-controlled study to determine the efficacy of Turmeric extract (BCM-95) with mild to moderate osteoarthritis. - Nil

Start Date16 Dec 2024

Sponsor / Collaborator

Arjuna Natural Pvt Ltd.

100 Clinical Results associated with Curcumin

100 Translational Medicine associated with Curcumin

100 Patents (Medical) associated with Curcumin

21,642

Literatures (Medical) associated with Curcumin

01 Dec 2025·HISTOCHEMISTRY AND CELL BIOLOGY

Novel role of curcumin as inhibitor of β-amyloid-induced lamin fragmentation

Article

Author: Park, Il-Seon ; Haque, Md. Aminul ; Hossain, Md. Selim ; Haque, Md Aminul ; Hossain, Md Selim

Oligomer amyloid beta 42 (Aβ) is considered the key pathogenic molecule in Alzheimer disease (AD) and causes specific lamin fragmentation. Curcumin has been recognized for its protective effects against Aβ-induced toxicity in AD, though its underlying mechanism remains unclear. In this study, the inhibitory mechanism of curcumin against Aβ-induced lamin fragmentation and cell death was investigated. Human neuroblastoma cells were used to examine Aβ-induced lamin fragmentation and lamin deformation by immunoblotting and confocal microscopy, while cell viability was measured using MTT and alamarBlue assay. Caspase and cathepsin L activity were assessed by spectrofluorometry, and Aβ aggregation was evaluated by ThT assay. Our results demonstrated that curcumin inhibited Aβ aggregation, reducing intracellular Aβ uptake by 45% compared to Aβ-treated cells. Curcumin also inhibited the Aβ-induced intracellular calcium rise, subsequently leading to a onefold reduction in cathepsin L activity. This reduction in cathepsin L activity by curcumin blocked the Aβ-induced lamin fragmentation. Collectively, these findings suggest that curcumin inhibits Aβ-induced cell death by preventing Aβ entry and lamin cleavage, providing potential new insights for AD treatment.

01 Dec 2025·HISTOCHEMISTRY AND CELL BIOLOGY

Fabrication of curcumin-incorporated human amniotic membrane extracellular matrix-derived scaffold to enhance full-thickness wound healing in diabetic rats

Article

Author: Nasiry, Davood ; Mehdinezhad Roshan, Mehdi ; Zarkesh, Ibrahim ; Kazemi Ashtiani, Mohammad ; Moharrami Kasmaie, Farshad ; Mazaheri Meybodi, Azadeh ; Erfanian, Saeideh ; Piryaei, Abbas ; Abdollahifar, Mohammad Amin

The multifactorial nature of diabetic wounds necessitates a mixed approach for successful treatment. Compensation of degenerated wound tissue extracellular matrix (ECM) and application of anti-inflammatory and antioxidant agents have been shown to be promising. Here, an attempt was made to fabricate a biocompatible wound dressing from curcumin-incorporated human amniotic membrane (HAM) ECM-derived scaffold to accelerate diabetic wound healing in rats. Therefore, after inducing diabetes, an excisional ischemic wound was created on rat skin, then treatments were administered for a period of 21 days. The main groups were the diabetic animals that received an engraftment of HAM scaffold (HAMS group) and the curcumin-incorporated HAMS (HAMS/β/C group). Evaluation at post-wounding days 7, 14, and 21 indicated that the parameters related to regeneration, including wound closure, volume of new epidermis and dermis, proliferating cells, fibroblasts, blood vessels, collagen deposition, and tensile strength, as well as transcripts of Vegf, bFgf, and Tgf-β genes of the healed wound in both HAMS and HAMS/β/C groups were considerably greater than those of the diabetic group. Conversely, the presence of inflammatory cells, i.e., neutrophils and macrophages, and the transcripts of Tnf-α and Il-1β showed a dramatic decrease in the treated groups relative to the diabetic group. Finally, compared to the HAMS group, considerable differences were found with the HAMS/β/C group in almost all evaluated parameters. Overall, these results suggest that using the complementary or synergistic effects of curcumin and HAMS could be a promising approach to improve diabetic wound healing.

01 Dec 2025·Recent patents on biotechnology

Curcumin-assisted Preparation of α-Fe₂O₃@TiO₂ Nanocomposites for Antibacterial and Photocatalytic Activity

Article

Author: Kar, Kamal K. ; Chamoli, Pankaj ; Kala, Anuskha ; Kimothi, Sanjeev ; Saini, Krati ; Verma, Rashmi

Background::

Harmful microorganisms like pathogens significantly impact human health. Meanwhile, industrial growth causes pollution and water contamination by releasing untreated hazardous waste. Effective treatment of these microorganisms and contaminants is essential, and nanocomposites may be a promising solution. The present attempt demonstrates the green synthesis of α-Fe2O3@TiO2 nanocomposites (FTNCs) for the effective treatment of pathogens and organic contaminants.

Methods::

The FTNCs have been synthesized through a green approach utilizing curcumin extract. Curcumin (Turmeric) extract (TEx) was prepared by washing, drying, and crushing 5 g of turmeric, then boiling it in 100 mL distilled water at 70°C for 1 hour. Metal salts (Fe3+/Ti4+, 2:1) were added to 100 mL of TEx under continuous stirring at 70°C for 24 h. The solution was rinsed and dried at 80°C overnight and heated at 300°C for 3 h to remove impurities.

Results::

Synthesized FTNCs have been tested for the potent antibacterial activity against both Gram-positive (Staphylococcus aureus, Bacillus subtilis, Enterococcus faecalis) and Gram-negative bacteria (Escherichia coli, Salmonella Abony, Pseudomonas sp.). Observations discovered noteworthy inhibition of both Gram-positive and Gramnegative bacteria by FTNCs. Furthermore, the FTNCs system shows the energy band gap of ~2.6 eV which may suppress electron recombination, thereby enhancing photocatalysis. The photo-degradation is examined against Evans blue (EB) and Congo red (CR) dyes under UV and visible light (125 W) irradiation. The remarkable photocatalytic degradation efficiency (DE) for CR reached ~67.4% in 60 min.

Conclusion::

A simple green approach has been demonstrated for the synthesis of the FTNCs using curcumin-mediated reduction. As prepared FTNCs have been evaluated for potent antibacterial activity against both Gram-positive (Staphylococcus aureus, Bacillus subtilis, Enterococcus faecalis) and Gram-negative bacteria (Escherichia coli, Salmonella Abony, Pseudomonas sp.). The results show that the highest zone of inhibition diameter values have been obtained for 5 mg/mL concertation of FTNCs of ~14, 22,18, 21, and 20 and 29 mm for E. coli, S. abony, S. aureus, B. subtilis, E. faecalis, and Pseudomonas sp., respectively. Additionally, FTNCs demonstrate remarkable photocatalytic degradation efficiency against EB and CR dyes under UV (125 W) irradiation, achieving 56, 67% degradation within 60 min, respectively. The findings indicate that FTNCs show long-term antimicrobial effectiveness and potential for water treatment through photocatalysis. This examination highlights recent advancements in intellectual property rights (IPR) and patent strategies, shedding light on how patents influence eco-friendly synthesis and the development of multifunctional, high-performance nanocomposites.

News (Medical) associated with Curcumin

28 Oct 2024

·www.prnewswire.com

Cocrystal Health Industry Announces Launch of Best in Class Bioabsorption and Stability Cocrystallized Lutein and Curcumin Technologies

Patented and clinically verified nutraceutical actives outperform current branded offerings and offer a powerful solution for supplement product potency concerns. LAS VEGAS, Oct. 28, 2024 /PRNewswire/ -- At the Supplyside West tradeshow this week representatives from Cocrystal Health Industry are announcing the launch of the Cocrystal Lutein and Curcumin powder actives. Backed by 60 global patents and near 100 published papers, the company leverages their proprietary and clean cocrystallization platform to produce actives with dramatically improved bioabsorption, stability and functionality relative to existing offerings. These launches build on their existing cocrystallized ingredient portfolio which includes Ubiquinol CoQ10, Hydroxytyrosol and Alpha Tocopherol Vitamin E. Continue Reading Cocrystal Curcumin Powder Cocrystal Lutein Powder Lutein is well demonstrated in clinical research to support eye health, though traditional lutein ingredients have poor bioabsorption, solubility, and stability, as the ingredient is easily oxidized. Powered by Cocrystal Health Industry's clean, vegan and non-GMO cocrystallization process, Cocrystal Lutein now provides a powerful solution to address these concerns. In 3rd party testing, Cocrystal Lutein demonstrated over 6 times greater bioabsorption and 3 times better solubility compared to current marketed lutein. In a head-to-head capsule stability study, the cocrystal advantage is even more dramatic. Cocrystal Lutein maintained over 99% of potency in capsules after 30 days, while current marketed lutein maintained less than 2% of its original potency. In addition to performance advantages, the cocrystal technology offers a significant cost savings relative to well known branded lutein. While well researched to support a range of benefits including joint and cognitive health, marketed curcumin extracts are similarly limited by very poor bioavailability. Patented Cocrystal Curcumin featuring L-Carnitine as a ligand has been shown in studies to offer over 10X greater bioabsorption in comparison to current marketed curcumin. And while there are several enhanced bioavailability curcumin materials available, in a head-to-head study Cocrystal Curcumin showed significantly better bioabsorption even relative to an existing enhanced offer. Alex Mei, PhD, Cocrystal Health Industry's Founder & CEO commented, "We are thrilled to expand our portfolio and introduce powerful new solutions in our Cocrystal Lutein & Curcumin technologies. Our proprietary platform solves for multiple nutrition brand concerns – providing meaningful differentiation and unparalleled benefit performance to their consumers, while ensuring sustained potency against label claim. As the global leader in cocrystallized active ingredients, we're proud to offer these transformative solutions." To learn more manufacturers and formulators can reach out to [email protected]. About Cocrystal Health Industry: Backed by 60 global patents and near 100 published papers, Cocrystal Health Industry introduces cocrystal powder technologies as unprecedented solutions for poor stability and low bioavailability ingredients. With demonstrated best in class bioavailability and superior in-formula stability, our actives also feature pure nature integrity, improved solubility, dissolution, melting point and flowability versus existing offerings. Beyond their superior performance, Cocrystal actives typically offer a cost advantage relative to other branded ingredients. The company's growing portfolio includes Cocrystal Ubiquinol, Hydroxytyrosol, Alpha Tocopherol, Rutin and now Lutein and Curcumin. For more information visit . Media Contact: Jeff Avila 305-632-1733 [email protected] SOURCE Cocrystal Health Industry WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

30 May 2024

·www.prnewswire.com

New Study Shows Petadolex Butterbur may be an Effective Supplement for Migraine Management

TAMPA, Fla., May 30, 2024 /PRNewswire/ -- A new review in the journal Practical Neurology highlights the efficacy of the supplement Petadolex in preventing migraines. The comprehensive review of "Nutraceuticals for Migraine Management" conducted by headache specialists Drs L. Denysenko and D. Kuruvilla details the effectiveness of four widely available supplements commonly used for migraine prevention. Only Petadolex has data to support reducing migraine frequency with "a predictable dose-response relationship." Continue Reading Only Petadolex has data to support reducing migraine frequency with "a predictable dose-response relationship." Post this Petadolex Butterbur Supplement Proven Effective for Migraine Management Petadolex, a patented preparation of the European butterbur plant, was compared to Coenzyme Q10 (CoQ10), Vitamin D, and Curcumin. Petadolex stands out with numerous clinical trials demonstrating its safety and efficacy as well as laboratory studies showing how and why it works. While Petadolex is derived from butterbur, unlike other available or generic butterbur supplements, it is a proprietary liquid extract of the plant which ensures that potentially toxic native butterbur chemicals are eliminated. The resulting supplement, Petadolex, has reliable, safe and effective pharmacology and contains a minimum 15% petasins and isopetasins, the essential active ingredients proven effective in patient studies. Petadolex, the only liquid form of butterbur used in clinical trials, has been shown to work by multiple mechanisms including inhibiting the release of calcitonin gene-related peptide (CGRP). CGRP, the brain chemical which plays a key role in causing migraine symptoms, is blocked or inhibited by the newest category of migraine prevention prescription drugs. Modifying CGRP is also a natural mechanism of Petadolex as well as blocking migraines by acting on select calcium channel pathways to desensitize sensory neurons. Dr. Lex Denysenko, the lead author of the review, notes: "Our review highlights the potential of butterbur liquid extract, particularly Petadolex, in migraine management. The evidence suggests butterbur may offer a valuable therapy for reducing migraine frequency and improving patient outcomes." For clinicians and individuals seeking natural alternatives to prescription drugs, Petadolex holds promise as a natural remedy for migraine prevention. To learn more about Petadolex and the benefits of its butterbur extract, visit . References About Petadolex Petadolex® butterbur supplement, manufactured by Linpharma, provides premium quality and efficacy for your health needs. Produced in Germany, where supplements are held to the same rigorous standards as medications, our products meet stringent safety and ingredient-purity benchmarks surpassing U.S. standards and domestically manufactured supplements. Backed by Weber & Weber, a renowned German OTC company with over 60 years of expertise in pharmaceuticals, herbal extracts, homeopathic products, and dietary supplements, Linpharma proudly represents these exceptional products in the USA and Canada. Learn more at SOURCE Linpharma

11 Dec 2023

·www.prnewswire.com

TRANSDERMAL CURCUMIN YIELDS PROMISING DATA FOR SICKLE CELL SUFFERERS PRESENTED AT ANNUAL AMERICAN SOCIETY OF HEMATOLOGY CONFERENCE IN SAN DIEGO, CALIFORNIA

Preclinical results show steady decline in pain, increase in red blood cell stability and reduction in inflammatory markers SAN DIEGO, Dec. 11, 2023 /PRNewswire/ -- Vascarta Inc. ("Vascarta") announced new research findings presented at the American Society of Hematology meeting in San Diego show that a novel transdermal preparation of curcumin from Vascarta reduced pain in humanized mice which suffer with the human form of sickle cell disease. As described in a poster*, several features of human sickle cell pain were measured in these humanized sickle cell mice including sensitivity to mechanical stimulus and cold. In cold conditions, the mice experienced significantly less pain after only hours of treatment and this effect continued during the full 21-day testing period. In room temperature conditions, the mice experienced less pain starting 14 days after first treatment. Mice treated with the transdermal curcumin also showed strong evidence of enhanced red blood cell stability including less hemolysis and improved hematocrit, redox balance and energy production. Additionally, both the liver and spleen showed evidence of improved health. Anti-inflammatory activity was demonstrated by a reduction of multiple markers of inflammation including deactivation of activated mast cells, which are significant contributors to chronic pain. Unlike curcumin taken orally, Vascarta's transdermal curcumin** is highly bioavailable; thus, therapeutic efficacy was achieved by applying only one drop to the abdomen every other day. "This transdermal curcumin formulation represents a potentially new safe and easy-to-deploy approach to sickle cell disease that could be used either for prevention or for treatment not only for chronic pain, but also for many of the other clinical consequences stemming from red cell instability," said Professor Kalpna Gupta (University of California – Irvine), principal investigator. Professor Joel Friedman (Albert Einstein College of Medicine and inventor of Vascarta's patented transdermal drug delivery technology) stated that "the positive sickle cell results are consistent with multiple other preclinical studies that have shown therapeutic benefits of transdermal curcumin for pain, inflammation, cytokine storm, endothelial integrity, hypertension, aging and more. We look forward to forming alliances with strategic partners to enable this novel technology to benefit patients suffering from any of several inflammatory diseases. " *"Mechanism-based Targeting of Sickle Cell Pathobiology and Pain with Novel Transdermal Curcumin" ** Formulated with Curcugen® (Dolcas-Biotech, LLC). About Sickle Cell Disease Sickle cell disease is the most common inherited disease that primarily affects African Americans and Hispanics in the United States, with ~50% of affected individuals suffering chronic pain. About Vascarta Vascarta is a startup pharmaceutical company exploring efficient transdermal delivery of pharmaceuticals to address inflammatory and blood diseases. More information regarding Vascarta's existing research or future collaborations can be found at . Poster Authors & Affiliations Yugal Goel1, Mya A. Arellano1, Raghda T. Fouda1, Daniel Kerr2, Sirsendu Jana7, Reina A. Lomeli1, Graham J. Velasco3, Probal Banerjee2, Donovan A. Argueta1, Mihir Gupta4, Richard Prince8, Abdu I, Alayash7, Joel Friedman5,8, Kalpna Gupta1,6 1,6Hematology/Oncology, Department of Medicine, University of California, Irvine, CA; 2Department of Chemistry and Center for Developmental Neuroscience, The College of Staten Island (CUNY), NY; 3Pathology Department, VA Long Beach Healthcare System, Long Beach, CA; 4Department of Neurosurgery, Yale University School of Medicine, New Haven, CT; 5Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY; 6Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN. 7Laboratory of Biochemistry and Vascular Biology, Center for Biologics Evaluation and Research Food and Drug Administration, Silver Spring, MD, 8Vascarta Inc. 4 Chatham Road, 2nd Floor Summit, NJ; 2Department of Chemistry and Center for Developmental Neuroscience, The College of Staten Island, NY. SOURCE Vascarta Inc

ASHClinical Result

100 Deals associated with Curcumin

External Link

KEGG	Wiki	ATC	Drug Bank
-	Curcumin	-	DB11672

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Inflammation	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Localized Prostate Carcinoma	Phase 3	US	The University of Texas Southwestern Medical Center	11 Mar 2019
Crohn Disease	Phase 3	FR	3i Nature SAS	01 Dec 2014
Colorectal Cancer	Phase 3	-	University of Pennsylvania	-
Colorectal Cancer	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Conjunctivitis, Allergic	Phase 3	-	University of Pennsylvania	-
Conjunctivitis, Allergic	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Optic Atrophy, Hereditary, Leber	Phase 3	-	The University of Texas MD Anderson Cancer Center	-
Optic Atrophy, Hereditary, Leber	Phase 3	-	University of Pennsylvania	-
Stomatitis	Phase 3	-	University of Pennsylvania	-
Stomatitis	Phase 3	-	The University of Texas MD Anderson Cancer Center	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02944578 (CTgov)	Phase 2	Uterine Cervical Dysplasia \| Cervical Intraepithelial Neoplasia	7	Curcumin (Curcumin)	kdjiqsuwmh(ztvpnacgwp) = ejdbmgfnsn ykvuiwrijh (nqwtrnumob, djezvjtxyz - vmlpubrest) View more	-	29 Oct 2024
				placebo (Placebo)	kdjiqsuwmh(ztvpnacgwp) = wgcptckdkh ykvuiwrijh (nqwtrnumob, jyxnvqhrwo - ezssttkule) View more
NCT03223883 (CTgov)	Phase 2	Cognitive Dysfunction \| Chronic Kidney Diseases	94	Curcumin (Curcumin)	jkopahzywo(cyslhwojcy) = ojibndelhg rjhyhmbsvc (qtjzwrxdyb, vryswwkksp - kbedahkvct) View more	-	08 Oct 2024
				Placebo (Placebo)	jkopahzywo(cyslhwojcy) = nyvqylgobp rjhyhmbsvc (qtjzwrxdyb, wgmstoqrfc - lnkpoiueal) View more
NCT04205929 (CTgov)	Phase 4	Hemorrhage \| Metrorrhagia	58	Placebo (Placebo Group)	zsjgmqyfqn(vqjkrcykes) = chlpyhyhnf orotbplpfu (zottxqruxs, wzhignfedm - acrftrvenh) View more	-	03 Jul 2024
				Curcumin (Curcumin Group)	zsjgmqyfqn(vqjkrcykes) = xrnpypdvhs orotbplpfu (zottxqruxs, mqyrqfdkyl - pymamptyld) View more
ENDO2024	Not Applicable	Pituitary Apoplexy	-	Curcumin	yoxlsbuedq(kmjwsafqvk) = dxulepmira esxoscjksm (cdlwqflwev ) View more	-	01 Jun 2024
				IV dexamethasone	yoxlsbuedq(kmjwsafqvk) = blhzxgwdni esxoscjksm (cdlwqflwev ) View more
NCT02100423 (CTgov)	Phase 2	Chronic Lymphocytic Leukemia \| B-Cell Lymphoma \| Small Lymphocytic Lymphoma	35	cholecalciferol+curcumin	bhwyrgoyir(btuxqixdgh) = upbrhnccfh qprjivhzjo (jwijmhkbdw, lgcnorqdxj - nodzltzivc) View more	-	12 Apr 2024
NCT02782949 (CTgov)	Phase 2	Carcinogenesis \| Gastritis, Atrophic \| Gastritis, Hypertrophic ... View more	50	Quality-of-Life Assessment+Curcumin (Arm I (Curcumin))	jgytklqmfk(hihnoghbrc) = fezkvozuxb eynylfbrkw (ajnglgoauk, qqxmbvfezu - hbvuklkcgd) View more	-	05 Mar 2024
				Quality-of-Life Assessment (Arm II (Placebo))	jgytklqmfk(hihnoghbrc) = hqhponnubo eynylfbrkw (ajnglgoauk, hlvgzuiwfg - bnitmdrept) View more
Pubmed \| Physiol Rep	Not Applicable	Dysmenorrhea \| Premenstrual Syndrome	76	Curcumin	mqkmqphixf(artctjlkor) = pvstcoobko ywbipfqzoe (wontojxiqt )	-	01 Jul 2023
EASL_LCS2023	Not Applicable	Hepatocellular Carcinoma	-	Curcumin	qzbippfniv(udoslyhixg) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR jayeccnpgu (svlpoowefo ) View more	-	20 Apr 2023
PD16-01 (AUA2023)	Not Applicable	Prostatic Cancer	-	Lactoferrin	igtlostoxm(xkfltsuitm) = fxrllfhaqd lmqmenlepo (nbkdlcnyfc )	-	01 Apr 2023
				Curcumin + Lactoferrin	igtlostoxm(xkfltsuitm) = xeskuvgzdt lmqmenlepo (nbkdlcnyfc )
EP-55 (EANM2022)	Not Applicable	-	-	Curcumin gold nanoparticles (C-AuNPs)	nwdqpciibi(ttggjokqcl) = 0.35 bmyyyzzkmf (uauwzlrkgn ) View more	-	22 Sep 2022

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis